Şunu aradınız:: multireżistenti (Maltaca - İngilizce)

skont dejta in vitro, sonidegib mhuwiex sottostrat ta’ p-gp, bcrr jew tal-proteina multireżistenti 2 (mrp2).
based on in vitro data, sonidegib is not a substrate of p-gp, bcrp or multi-resistance protein 2 (mrp2).

ceritinib għandu wkoll distribuzzjoni preferenzjali ħafifa għaċ-ċelluli ħomor tad-demm, relattiva għall-plażma, bi proporzjon medja in vitro demm-plażma ta’ 1.35. studji in vitro jissuġġerixxu li ceritinib hu sottostrat għal p-glkoproteina (p- gp), imma mhux ta’ proteina reżistenti għall-kanċer tas-sider (bcrp) jew għal proteina 2 multireżistenti (mrp2).
ceritinib also has a slight preferential distribution to red blood cells, relative to plasma, with a mean in vitro blood-to-plasma ratio of 1.35. in vitro studies suggest that ceritinib is a substrate for p-glycoprotein (p-gp), but not of breast cancer resistance protein (bcrp) or multi-resistance protein 2 (mrp2).